Navigation Links
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Date:11/4/2008

n of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obl
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis Pharmaceuticals, ... it has earned a $4 million milestone payment ... associated with the initiation of a Phase 3 ... resistant (MDR), gram-negative bacterial infections.  The Phase 3 ... evaluate the efficacy and safety of plazomicin compared ...
(Date:9/17/2014)... ALTO, Calif. , Sept. 17, 2014  Neuraltus ... the Company,s Phase 2 clinical program of NP001 for ... Lou Gehrig,s disease) are being highlighted today in ... the ALS Research Group , being held in ... to a  post hoc  analysis, administration of a high ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
(Date:9/17/2014)... DMG Productions announces the upcoming airing ... broadcast on Wednesday, September 24, 2014 at 7:30 ... episode, Innovations will go behind the scenes to ... each client the opportunity to achieve the highest ... principles of Care, Compassion, and Commitment. , Audiences ...
(Date:9/17/2014)... 2014 Kristen Yarker, MSc, RD recently announced ... children 9 months to 2 years old who are seeking ... picky eaters from developing by encouraging healthy eating habits from ... to 2 years): How to Transition From Baby Food to ... the Nutrition They Need)” is a new online seminar based ...
(Date:9/17/2014)... Wailea, Maui, HI (PRWEB) September 17, 2014 ... has announced the eighth annual Wailea Tennis Fantasy ... 19-23, 2014 at Maui’s prestigious Wailea Tennis Club, with ... ranked Lindsay Davenport returning to Wailea, Maui for her ... world-class instruction and match play with Davenport, recently inducted ...
(Date:9/17/2014)... In a new video released for ... expert on the condition known as PPP, demonstrates a proven ... or PPP, is a condition that affects mostly uncircumcised men ... affected as well. The condition is characterized by small bumps ... is not a sexually transmitted disease and generally has no ...
(Date:9/17/2014)... 17, 2014 Request A Test , ... is offering 10% off drug testing through the ... drug tests, including those ordered by employers for workplace or ... of this discount by using promo code DRUG10 when placing ... positives on workplace drug testing, especially for marijuana or THC. ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 3Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... from University of Missouri, Columbia indicates that the masculine tendencies ... been assumed all along that such tendencies were the barriers ... this issue. ,Generally it has been said that ... quality is said to aid in their recovery in traumatic ...
... major Ranbaxy Laboratories Ltd says it has obtained tentative approval ... market a drug for insomnia. ,The US unit ... Drugs, US FDA, has determined the Ranbaxy formulations of Zolpidem ... therapeutic effect as that of Ambien tablets of Sanofi Aventis ...
... Health Services called Frontpoint Systems (http://www.frontpointsystems.co.uk /weblog) has ... Royal College of Obstetricians & Gynaecologists indicating a ... ,The site highlights what is wrong ... in the UK has published a letter from ...
... of Virginia Health System suggests that composition of plaque deposits ... a stroke. ,Published in the March edition of ... deposits in the carotid arteries of 102 patients treated at ... likely to have a stroke, physicians may want to take ...
... the risk of death among children aged 12 to 48 ... conducted by researchers at the Johns Hopkins Bloomberg School of ... in mortality among children 1 to11 months of age. The ... The Lancet. ,Zinc is one of the ...
Cached Medicine News:Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3Health News:More Evidence of Racial Discrimination in the NHS 2Health News:Calcium in Arterial Plaque is a Good Indicator for Risk of Stroke 2Health News:Zinc Supplements Enhance Immunity in Children 2
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Medicine Products: